Surrozen (SRZN) Other Non-Current Liabilities (2021 - 2026)
Surrozen (SRZN) recorded quarterly Other Non-Current Liabilities of $148.9 million in Q1 2026, up 32.32% quarter-over-quarter from $112.5 million in Q4 2025, and up 251.04% on a YoY basis from $42.4 million in Q1 2025.
Surrozen (SRZN) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Surrozen's Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $148.9 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 251.04% year-over-year to $148.9 million; the TTM figure through Mar 2026 stood at $148.9 million (up 251.04% YoY), while the FY2025 annual figure was $112.5 million, changed N/A from the prior year.
- Other Non-Current Liabilities was $148.9 million for Q1 2026 at Surrozen, up from $112.5 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $148.9 million in Q1 2026 to a low of $115000.0 in Q4 2023.
- Historically, Other Non-Current Liabilities has averaged $29.1 million across 5 years, with a median of $1.6 million in 2022.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities plunged 96.07% in 2022, then jumped 23733.15% in 2025.
- A 5-year view of Other Non-Current Liabilities shows it stood at $326000.0 in 2022, then tumbled by 64.72% to $115000.0 in 2023, then surged by 31387.83% to $36.2 million in 2024, then surged by 210.81% to $112.5 million in 2025, then jumped by 32.32% to $148.9 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $148.9 million (Q1 2026), $112.5 million (Q4 2025), and $53.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 148.92 Mn |
| Dec 31, 2025 | 112.55 Mn |
| Sep 30, 2025 | 53.54 Mn |
| Jun 30, 2025 | 32.62 Mn |
| Mar 31, 2025 | 42.42 Mn |
| Sep 30, 2024 | 36.21 Mn |
| Jun 30, 2024 | 33.03 Mn |
| Mar 31, 2024 | 178,000.00 |
| Dec 31, 2023 | 115,000.00 |
| Sep 30, 2023 | 243,000.00 |
| Jun 30, 2023 | 326,000.00 |
| Mar 31, 2023 | 591,000.00 |
| Dec 31, 2022 | 326,000.00 |
| Sep 30, 2022 | 1.33 Mn |
| Jun 30, 2022 | 1.38 Mn |
| Mar 31, 2022 | 1.80 Mn |
| Dec 31, 2021 | 8.30 Mn |
| Sep 30, 2021 | 8.31 Mn |
| Jun 30, 2021 | 5.14 Mn |
| Mar 31, 2021 | 2.60 Mn |